COVID-19 and Neuromyelitis Optica Disorder: A Need for Guidance-Based Management
Little guidance has been issued on how to manage patients with COVID-19 and coexisting neurological disorders.
Neurodegenerative Diseases
How Healthcare Conversations Are Impacted by Pseudobubar Affect in Patients With ALS
A majority of patients with ALS and a diagnosis of pseudobulbar affect do not believe their PBA symptoms have an effect on healthcare conversations.
The Relationship Between Gut Microbiota and Neurodegenerative Disorders
The microbiota-gut-brain axis represents a bidirectional communication pathway through which the gut microbiota may influence the CNS.
Patients With Huntington Disease Frequently Report Emotional Issues, Fatigue, and Difficulty Thinking
Researchers found emotional issues, fatigue, and difficulties in thinking represent common symptomatic themes in patients with Huntington disease.
MRI-Based Small Vessel Disease Score Predicts Risk for Dementia
A simple SVD score using MRI scans, may aid in identifying patients with SVD who are likely to develop cognitive decline.
Verdiperstat Fast-Tracked for Multiple System Atrophy
The Food and Drug Administration has granted Fast Track designation to verdiperstat (BVH-3241; Biohaven) for the treatment of multiple system atrophy.
Increased Serum NfL Indicates Ongoing Neuroinflammation, May Predict Neurodegeneration in Early MS
Serum NfL levels are indicative of ongoing neuroinflammation and may be predictive of neurodegeneration in patients with early MS.
Novel Therapy for Progressive Supranuclear Palsy Gets Orphan Drug Designation
The FDA has granted Orphan Drug designation to RT001 (Retrotope) for the treatment of progressive supranuclear palsy (PSP).
Predicting Amyloid Accumulation in Patients With Objective Subtle Cognitive Difficulties
The presence of objective subtle cognitive difficulties (Obj-SCD) on neuropsychological measures may predict faster amyloid accumulation and neurogenerative changes.
Inebilizumab Shows Promise in Neuromyelitis Optica Spectrum Disorder
Inebilizumab is superior to placebo in reducing the risk for a neuromyelitis optica spectrum disorder attack.
-
Loading...
-
Loading...
Next post in Neurodegenerative Diseases
